Bölüm 1

Serviksin Preinvaziv Hastalığı, 1

• Arbyn M, Bergeron C, Klinkhamer P, et al: Liquid compared with conventional cervical cytology: A systematic review and meta-analysis, Obstet Gynecol 111:167–177, 2008.
• Boardman LA, Adams AE, Peipert JF: Clinical predictors of cervical intraepithelial neoplasia 2 or greater in women with mildly abnormal Pap smears, J Reprod Med 47:891–896, 2002.
• Boyce JG, Fruchter RG, Romanzi L, et al: The fallacy of the screening interval for cervical smears, Obstet Gynecol 76:627–632, 1990.
• Camargo MJ, Russomano FB, Tristão MA, et al: Large loop versus straight-wire excision of the transformation zone for treatment of cervical intraepithelial neoplasia: a randomised controlled trial of electrosurgical techniques, BJOG 122:552–557, 2015.
• Castellsague X, Bosch FX, Munoz N, et al, for the International Agency for Research on Cancer Multicenter Cervical Cancer Study Group: Male circumcision, penile human papillomavirus infection, and cervical cancer in female partners, N Engl J Med 346:1105–1112, 2002.
• Castle PE, Schiffman M, Bratti MC, et al: A population-based study of vaginal human papillomavirus infection in hysterectomized women, J Infect Dis 190:458–467, 2004.
• Castle PE, Sideri M, Jeronimo J, et al: Risk assessment to guide the prevention of cervical cancer, Am J Obstet Gynecol 197(4):356.e1–356.e6, 2007.
• Castle PE, Schiffman M, Wheeler CM, et al: Evidence for frequent regression of cervical intraepithelial neoplasia—Grade 2, Obstet Gynecol 113:18–25, 2009.
• Castle PE, Kreimer AR, Wacholder S, et al: Influence of loop electrosurgical excision procedure on subsequent acquisition of new human papillomavirus infections, J Infect Dis 199:1612–1620, 2009.
• Castle PE, Gage JC, Wheeler CM, et al: The clinical meaning of a cervical intraepithelial neoplasia grade 1 biopsy, Obstet Gynecol 118:1222–1229, 2011.
• Chen D, Cui T, Ek WE, et al: Analysis of the genetic architecture of susceptibility to cervical cancer indicates that common SNPs explain a large proportion of the heritability, Carcinogenesis 36(9):992–998, 2015.
• Clarke MA, Wentzensen N, Mirabello L, et al: Human papillomavirus DNA methylation as a potential biomarker for cervical cancer, Cancer Epidemiol Biomarkers Prev 21:2125–2137, 2012.
• Costa S, Venturoli S, Negri G, et al: Factors predicting the outcome of conservatively treated adenocarcinoma in situ of the uterine cervix: an analysis of 166 cases, Gynecol Oncol 124:490–495, 2012.
• Cuzick J, Cadman L, Mesher D, et al: Comparing the performance of six human papillomavirus tests in a screening population, Br J Cancer 108:908–913, 2013.
• Dillner J, Rebolj M, Birembaut P, et al: Joint European Cohort Study. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study, BMJ 337:a1754, 2008.
• Eddy DM: Screening for cervical cancer, Ann Intern Med 113: 214–216, 1990.
• Elfgren K, Kalantari M, Moberger B, et al: A population-based five-year follow-up study of cervical human papillomavirus infection, Am J Obstet Gynecol 183:561–567, 2000.
• Erickson CC, Everett BE, Graves LM, et al: Population screening for uterine cancer by vaginal cytology: Preliminary summary of results of first examination of 108,000 women and second testing of 33,000 women, JAMA 162:167–173, 1956.
• Figge DC, Creasman WT: Cryotherapy in the treatment of cervical intraepithelial neoplasia, Obstet Gynecol 62:353–358, 1983.
• Flagg EW, Datta SD, Saraiya M, et al: Population-based surveillance for cervical cancer precursors in three central cancer registries, United States 2009, Cancer Causes Control 25:571–581, 2014.
• Fukuda K, Hachisuga T, Nakamura S, et al: Local immune response in persistent cervical dysplasia, Obstet Gynecol 82:941–945, 1993.
• Gage JR, Meyers C, Wettstein FO: The E& proteins of the nononcogenic human papillomavirus type 6b (HPV-6b) and of the oncogenic HPV-16 differ in retinoblastoma protein binding and other properties, J Virol 64:723–730, 1990.
• Giuliano AR, Nyitray AG, Kreimer AR, et al: EUROGIN 2014 roadmap: Differences in human papillomavirus infection natural history, transmission and human papillomavirus-related cancer incidence by gender and anatomic site of infection, Int J Cancer 136:2752–2760, 2015.
• Gonzalez P, Hildesheim A, Rodriguez AC, et al: Behavioral/lifestyle and immunologic factors associated with HPV infection among women older than 45 years, Cancer Epidemiol Biomarkers Prev 19:3044–3054, 2010.
• Greenberg MD, Reid R, Schiffman M, et al: A prospective study of biopsy-confirmed cervical intraepithelial neoplasia grade 1: Colposcopic, cytological, and virological risk factors for progression, J Low Genit Tract Dis 3:104–110, 1999.
• Gustafsson L, Ponten J, Zack M, et al: International incidence rates of invasive cervical cancer after introduction of cytological screening, Cancer Cause Control 8:755–763, 1997.
• Halec G, Alemany L, Lloveras B, et al, Retrospective International Survey and HPV Time Trends Study Group; Retrospective International Survey and HPV Time Trends Study Group: Pathogenic role of the eight probably/possibly carcinogenic HPV types 26, 53, 66, 67, 68, 70, 73 and 82 in cervical cancer, J Pathol 234:441–451, 2014.
• Hariri S, Unger ER, Sternberg M, et al: Prevalence of genital human papillomavirus among females in the United States, the National Health and Nutrition Examination Survey, 2003-2006, J Infect Dis 204:566–573, 2011.
• Henk JH, Insinga RP, Singhal PK, et al: Incidence and costs of cervical intraepithelial neoplasia in a US commercially insured population, J Lower Genit Tract Dis 14:29–36, 2010.
• Hildesheim A, Schiffman M, Bromley C, et al: Human papillomavirus type 16 variants and risk of cervical cancer, J Natl Cancer Inst 93:315–318, 2001.
• Ho GYF, Burk RD, Klein S, et al: Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia, J Natl Cancer Inst 87:1365–1371, 1995.
• Hogewoning CJA, Bleeker MCG, van den Brule AJC, et al: Condom use promotes regression of cervical intraepithelial neoplasia and clearance of human papillomavirus: A randomized clinical trial, Int J Cancer 107:811–816, 2003.
• Huh WK, Ault KA, Chelmow D, et al: Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance, J Low Genit Tract Dis 19:91–96, 2015.
• International Collaboration of Epidemiological Studies of Cervical Cancer, Appleby P, Beral V, et al: Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies, Lancet 370: 1609–1621, 2007.
• International Collaboration of Epidemiological Studies of Cervical Cancer: Cervical carcinoma and sexual behavior: collaborative reanalysis of individual data on 15,461 women with cervical carcinoma and 29,164 women without cervical carcinoma from 21 epidemiological studies, Cancer Epidemiol Biomarkers Prev 18:1060–1069, 2009.
• International Collaboration of Epidemiological Studies of Cervical Cancer: Cervical carcinoma and reproductive factors: collaborative reanalysis of individual data on 16,563 women with cervical carcinoma and 33,542 women without cervical carcinoma from 25 epidemiological studies, Int J Cancer 119:1108–1124, 2006.
• International Collaboration of Epidemiological Studies of Cervical Cancer: Comparison of risk factors for invasive squamous cell carcinoma and adenocarcinoma of the cervix: collaborative reanalysis of individual data on 8,097 women with squamous cell carcinoma and 1,374 women with adenocarcinoma from 12 epidemiological studies, Int J Cancer 120:885–891, 2007.
• Jakobsson M, Gissler M, Paavonen J, et al: Long-term mortality in women treated for cervical intraepithelial neoplasia, BJOG 116:838–844, 2009.
• Kalliala I, Anttila A, Pukkala E, et al: Risk of cervical and other cancers after treatment of cervical intraepithelial neoplasia: retrospective cohort study, BMJ 331:1183–1185, 2005.
• Katki HA, Schiffman M, Castle PE, et al: Benchmarking CIN 3+ risk as the basis for incorporating HPV and Pap cotesting into cervical screening and management guidelines, J Low Genit Tract Dis 17:S28–S35, 2013.
• Kinney W, Sung HY, Kearney KA, et al: Missed opportunities for cervical cancer screening of HMO members developing invasive cervical cancer (ICC), Gynecol Oncol 71:428–430, 1998.
• Kjaer S, Hogdall E, Frederiksen K, et al: The absolute risk of cervical abnormalities in high-risk human papillomavirus-positive, cytologically normal women over a 10-year period, Cancer Res 66:10630–10636, 2006.
• Khan MJ, Castle PE, Lorincz AT, et al: The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice, J Natl Cancer Inst 97:1072–1079, 2005.
• Le T, Guijon F: Human papillomavirus infections and cervical intraepithelial neoplasia in renal transplant patients, J Lower Genit Tract Dis 3:155–158, 1999.
• Luhn P, Walker J, Schiffman M, et al: The role of co-factors in the progression from human papillomavirus infection to cervical cancer, Gynecol Oncol 128:265–270, 2013.
• Marks M, Gravitt PE, Gupta SB, et al: Combined oral contraceptive use increases HPV persistence but not new HPV detection in a cohort of women from Thailand, J Infect Dis 204:1505–1513, 2011.
• Massad LS, Einstein MH, Huh WK, et al, for the 2012 ASCCP Consensus Guidelines Conference: 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors, J Low Genit Tract Dis 17:S1–S27, 2013.
• McAllum B, Sykes PHH, Sadler L, et al: Is the treatment of CIN2 always necessary in women under 25 years old?, Am J Obstet Gynecol 205:478.e1–478.e7, 2011.
• McCredie MRE, Sharples KJ, Paul C, et al: Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: A retrospective cohort study, Lancet Oncol 9:425–434, 2008.
• Molling JW, de Gruijl TD, Glim J, et al: CD4(+)CD25hi regulatory T-cell frequency correlates with persistence of human papillomavirus type 16 and T helper cell responses in patients with cervical intraepithelial neoplasia, Int J Cancer 121: 1749–1755, 2007.
• Moscicki AB, Ma Y, Wibbelsman C, et al: Rate of and risks for regression of cervical intraepithelial neoplasia 2 in adolescents and young women, Obstet Gynecol 116:1373–1380, 2010.
• Papanicolaou GN, Traut HF: The diagnostic value of vaginal smears in carcinoma of the uterus, Am J Obstet Gynecol 42:193–206, 1941.
• Quinn M, Babb P, Jones J, et al: Effect of screening on incidence of and mortality from cancer of cervix in England: evaluation based on routinely collected statistics, BMJ 318:904–908, 1999.
• Richart RM: Natural history of cervical intraepithelial neoplasia, Clin Obstet Gynecol 10:748–784, 1967.
• Rintala MAM, Grenman SE, Puranen MH, et al: Transmission of high-risk human papillomavirus HHPV) between parents and infant: a prospective study of HPV in families in Finland, J Clin Microbiol 43:376–381, 2005.
• Rodriguez AC, Schiffman M, Herrero R, et al: Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3:critical role of duration of infection, J Natl Cancer Inst 102:1–10, 2010.
• Rodriguez AC, Schiffman M, Herrero R, et al: Low risk of type-specific carcinogenic HPV re-appearance with subsequent cervical intraepithelial neoplasia grade 2/3, Int J Cancer 131: 1874–1881, 2012.
• Rositch AF, Burke AE, Viscidi RP, et al: Contributions of recent and past sexual partnerships on incident human papillomavirus detection: acquisition and reactivation in older women, Cancer Res 72:6183–6190, 2012.
• Sanjose S, Quint WGV, Alemany L, et al: Human papillomavirus genotype attribution in invasive cervical cancer: A retrospective cross-sectional worldwide study, Lancet Oncol 11:1048–1056, 2010.
• Sasieni P, Castanon A, Cuzick J: Effectiveness of cervical screening with age: Population based case-control study of prospectively recorded data, BMJ 339:b2968, 2009.
• Schiffman S, Gary Clifford G, Buonaguro FM: Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline, Infect Agent Cancer 4:8, 2009.
• Sellors JW, Karwalajtys TL, Kaczorowski J, et al, for the Survey of HPV in Ontario Women (SHOW) Group: Incidence, clearance, and predictors of human papillomavirus infection in women, Can Med Assoc J 168:421–425, 2003.
• Serraino D, Gini A, Taborelli M, et al, for the IMPATTO-CERVICE Working Group: Changes in cervical cancer incidence following the introduction of organized screening in Italy, Prev Med 75:56–63, 2015.
• Sharp L, Cotton S, Little J, et al, on behalf of the TOMBOLA group: Psychosocial impact of alternative management policies for low-grade cervical abnormalities: Results from the TOMBOLA randomised controlled trial, PLoS ONE 8:e80092, 2013.
• Southern SA, Herrington CS: Disruption of cell cycle control by human papillomaviruses with special reference to cervical carcinoma, Int J Gynecol Cancer 10:263–274, 2000.
• Stanhope CR, Phibbs GD, Stuart GC, et al: Carbon dioxide laser surgery, Obstet Gynecol 61:624–627, 1983.
• Strander B, Andersson-Ellstrom A, Milsom I, et al: Long term risk of invasive cancer after treatment for cervical intraepithelial neoplasia grade 3: population based cohort study, BMJ 335:1077, 2007.
• Sung HY, Kearney KA, Miller Marie M, et al: Papanicolaou smear history and diagnosis of invasive cervical carcinoma among members of a large prepaid health plan, Cancer 88:2283–2289, 2000.
• Thomas DB, Ray RM, Kuypers J, et al: Human papillomaviruses and cervical cancer in Bangkok. III. The role of husbands and commercial sex workers, Am J Epidemiol 153:740–748, 2001.
• Thomas KK, Hughes JP, Kuypers JM, et al: Concurrent and sequential acquisition of different genital human papillomavirus types, J Infect Dis 182:1097–1102, 2000.
• Trimble CL, Piantadosi S, Gravitt P, et al: Spontaneous regression of high-grade cervical dysplasia: Effects of human papillomavirus type and HLA phenotype, Clin Cancer Res 11:4717–4723, 2005.
• Van der Marel J, Quint WGV, Schiffman M, et al: Molecular mapping of high-grade cervical intraepithelial neoplasia shows etiological dominance of HPV-16, Int J Cancer 131:E946–E953, 2012.
• Vinokurova S, Wentzensen N, Einenkel J, et al: Clonal history of papillomavirus-induced dysplasia in the female lower genital tract, J Natl Cancer Inst 97:1816–1821, 2005.
• Wentzensen N, Nason M, Schiffman M, et al, for the New Mexico HPV Pap Registry Steering Committee: No evidence for synergy between human papillomavirus genotypes for the risk of high-grade squamous intraepithelial lesions in a large population-based study, J Infect Dis 209:855–864, 2014.
• Wetta LA, Matthews KS, Kemper ML, et al: The management of cervical intraepithelial neoplasia during pregnancy: is colposcopy necessary?, J Low Genit Tract Dis 13:182–185, 2009.
• Winer RL, Lee SK, Hughes JP, et al: Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students, Am J Epidemiol 157:218–226, 2003.
• Zelmanowicz AM, Schiffman M, Herrero R, et al: Family history as a co-factor for adenocarcinoma and squamous cell carcinoma of the uterine cervix: Results from two studies conducted in Costa Rica and the United States, Int J Cancer 116:599–605, 2005.